Giant Cell Tumours of the Tendon Sheath: Lack of Correlation between nm23-H1 Expression and Recurrence

2004 ◽  
Vol 29 (1) ◽  
pp. 67-70 ◽  
Author(s):  
P. LORÉA ◽  
H. VAN DE WALLE ◽  
L. KINNEN ◽  
P. LEDOUX ◽  
J-P. MOERMANS ◽  
...  
Keyword(s):  
Clinical Outcome ◽  
Giant Cell ◽  
Tendon Sheath ◽  
Immunohistochemical Detection ◽  
Biological Factors ◽  
Down Regulation ◽  
Giant Cell Tumours

Some authors attribute recurrences of giant cell tumours to biological factors which are only expressed in some tumours. Grover et al. (1998) suggested that the risk for recurrence is associated with the down-regulation of the nm23-H1 gene. We reviewed the charts of the 154 patients operated on for giant cell tumours of the tendon sheath and selected a group of patients with recurrence (ten cases) and a group of patients who did not have a recurrence after a minimum follow-up of 3 years (13 cases). Immunohistochemical detection of nm23-H1 was performed blindly of the clinical outcome on the paraffin-embedded specimens of these patients and no correlation was found between nm23-H1 expression and the risk for recurrence.

GIANT CELL TUMOURS OF TENDON SHEATH OF HAND: CAUSES AND STRATEGIES TO PREVENT RECURRENCE

Hand Surgery ◽  
2011 ◽  
Vol 16 (02) ◽  
pp. 149-154 ◽  
Author(s):  
Azal Jalgaonkar ◽  
Baljinder Dhinsa ◽  
Howard Cottam ◽  
Ganapathyraman Mani
Keyword(s):  
Risk Factors ◽  
Local Recurrence ◽  
Giant Cell ◽  
Recurrence Rate ◽  
Case Series ◽  
Tendon Sheath ◽  
Giant Cell Tumours ◽  
High Incidence ◽  
The Mean

Giant cell tumours of tendon sheath of hand present a surgical dilemma due to their high incidence of local recurrence. We present a case series of 46 patients with 47 histologically confirmed giant cell tumours of tendon sheath over a ten-year period from 1998 to 2008. The mean follow-up was 47 months (range 25–124 months). We identified tumours with bony erosions and piecemeal resections as predictors of recurrence. Our recurrence rate of 9% was at the lower end of spectrum of previously published reports (range 7%–44%). We recommend "en-masse" excision of these tumours. All the patients with suspicion of these tumours should have preoperative radiographs to identify erosions. A thorough curettage of the bone should be done in cases with osseous erosion to prevent recurrence. Patients with these risk factors should be followed up annually for five years and be warned about recurrence.

Giant Cell Tumours of Tendon Sheath: Classification and Recurrence Rate

2001 ◽  
Vol 26 (1) ◽  
pp. 72-75 ◽  
Author(s):  
M. M. AL-QATTAN
Keyword(s):  
Prospective Study ◽  
Giant Cell ◽  
Giant Cell Tumour ◽  
Tendon Sheath ◽  
Type I ◽  
Type Ii ◽  
Giant Cell Tumours ◽  
The Mean ◽  
A Prospective Study

Forty-three consecutive cases of giant cell tumour of tendon sheath were included in a prospective study. The tumours were classified into two main types, depending on whether the entire tumour was, or was not, surrounded by one pseudocapsule as assessed by the surgeon during surgery. Each type was then sub-classified according to the thickness of the capsule, lobulation of the tumour, the presence of satellite lesions, and the diffuse or multicenteric nature of the tumour: these factors were also assessed by the surgeon. The mean follow-up period was 4 (range, 2–6) years. None of the type I tumours ( n=30) recurred, but recurrence occurred in five out of 13 type II tumours. Second recurrences were seen with type II B and C, but not type II A tumours.

GIANT CELL TUMOUR OF TENDON SHEATH OF TENDOACHILLES-A CASE REPORT

2021 ◽  
pp. 10-11
Author(s):  
K Srinivasa Reddy ◽  
K Anusha ◽  
K B Vijaya Mohan Reddy
Keyword(s):  
Case Report ◽  
Giant Cell ◽  
Giant Cell Tumour ◽  
Tendon Sheath ◽  
Cell Tumour ◽  
High Rate ◽  
Uncommon Tumour

Giant cell tumour arises from the synovium of tendon sheath, joints, or bursae,mostly affects adults between 30 and 50 years of age, and is slightly more common in females.Giant cell tumour of tendon sheath of tendoachilles is uncommon tumour. Usually it has a high rate of recurrence. In this article we report the case of a 32 year old female with Giant cell tumour of tendoachilles treated by excision with no reccurence after 7 months of follow up

scholarly journals Clinical outcome of operative treatment in 18 cases of giant cell tumors of bones

2020 ◽  
Vol 10 (2) ◽  
pp. 67-71
Author(s):  
Suresh Pandey
Keyword(s):  
Clinical Outcome ◽  
Giant Cell ◽  
De Novo ◽  
Excellent Result ◽  
Giant Cell Tumors ◽  
Musculoskeletal Tumor ◽  
Musculoskeletal Tumor Society ◽  
Non Union ◽  
Proximal Fibula

Background: Giant Cell Tumor of the bone (GCTB) has got variable outcome after the different methods of surgical treatment depending upon the site and grade of lesion and extent of tumor removal. This retrospective prospective analysis of operatively treated cases of GCTB of different sites aimed to highlight the clinical outcome. Methods: This was a prospective observational study of 18 cases of GCTB; proximal tibia (n=6), distal femur (n=5), distal radius (n=4), proximal femur (n=1), proximal fibula (n=1) and anterior arc of first rib (n=1) treated with different operative management with mean follow up of 53.61 months. Functional outcome with Musculoskeletal Tumor Society Score (MSTS), recurrence and complications were analyzed with at least 24 months of follow up. Results: There were 10 females and 8 males with average age at presentation 27.3 years (range 15-38). Average duration of symptom was 4.72 months. 2 were cases of recurrence previously op­erated and 16 were de novo cases. Mean MSTS was 84.27% with good to excellent result in 88%. There were no non-union, graft failure, metastasis, prosthetic failure or wound infection till at least 24 months of follow up in any of the cases. Conclusions: Extended curettage or reconstruction with auto graft in grade I and II tumor or en­doprosthesis in higher grade or recurrence of GCTB can give good to excellent functional result in majority of the cases.

GIANT CELL TUMOR OF TENDON SHEATH MIMICKING PYOGENIC GRANULOMA IN THE INDEX FINGER PULP: A CASE REPORT

Hand Surgery ◽  
2012 ◽  
Vol 17 (01) ◽  
pp. 125-127
Author(s):  
J. Terrence Jose Jerome ◽  
Kumar Venkatesan ◽  
Amarnath G ◽  
Usha Rani ◽  
Rohini Sridhar
Keyword(s):  
Giant Cell Tumor ◽  
Giant Cell ◽  
Clinical Presentation ◽  
Index Finger ◽  
Pyogenic Granuloma ◽  
Tendon Sheath ◽  
Cell Tumor ◽  
Complete Excision ◽  
Study Base

We report a 75-year-old man who presented with a painless friable mass in the index finger pulp mimicking pyogenic granuloma. Complete excision of the mass was done. The radiological and the histopathological findings suggested giant cell tumor of the tendon sheath. The patient had no recurrence at the end of a two-year follow-up. This unusual clinical presentation of the giant cell tumor of the tendon sheath was our study base and adds up to its variant presentation in the literature.

BILATERAL SYMMETRICAL GIANT CELL TUMOURS OF THE THUMB

Hand Surgery ◽  
2003 ◽  
Vol 08 (02) ◽  
pp. 237-238 ◽  
Author(s):  
S. Dalal ◽  
S. H. Bostock
Keyword(s):  
Case Report ◽  
Giant Cell ◽  
Tendon Sheath ◽  
Multiple Lesions ◽  
Giant Cell Tumours

Giant cell tumours of tendon sheath are common in the hand but multiple lesions are relatively rare. A case report of bilateral symmetrical involvement is presented and discussed.

Giant Cell Tumor of the Tendon Sheath Around the Foot and Ankle

2015 ◽  
Vol 105 (3) ◽  
pp. 249-254 ◽  
Author(s):  
Gauresh Vargaonkar ◽  
Vikramadittya Singh ◽  
Sumit Arora ◽  
Abhishek Kashyap ◽  
Vikas Gupta ◽  
...  
Keyword(s):  
Giant Cell Tumor ◽  
Giant Cell ◽  
Surgical Excision ◽  
Tendon Sheath ◽  
Cell Tumor ◽  
Flexor Hallucis Longus ◽  
Rare Clinical Entity ◽  
Foot And Ankle ◽  
Peroneus Brevis

The foot and ankle are rare sites of involvement for giant cell tumor of tendon sheath. We present three rare cases of giant cell tumor of tendon sheath arising from the tendon sheaths of the flexor hallucis longus, peroneus brevis, and extensor hallucis brevis tendons, along with a literature review of such cases in the foot and ankle region. All of the patients were treated with surgical excision of the mass and were asymptomatic after minimum follow-up of 18 months. Giant cell tumor of tendon sheath involving the foot and ankle region is a rare clinical entity, and good results can be expected after surgical excision.

Measurement of Invasive Potential Provides an Accurate Prognostic Marker for Giant Cell Tumour of Tendon Sheath

1998 ◽  
Vol 23 (6) ◽  
pp. 728-734 ◽  
Author(s):  
R. GROVER ◽  
A. O. GROBBELAAR ◽  
P. I. RICHMAN ◽  
P. J. SMITH
Keyword(s):  
Giant Cell ◽  
Prognostic Marker ◽  
Significant Risk ◽  
Tendon Sheath ◽  
Clinicopathological Parameters ◽  
Invasive Potential ◽  
Local Infiltration ◽  
Molecular Oncology ◽  
Giant Cell Tumours ◽  
Predicting Outcome

Giant cell tumours of tendon sheath vary from solitary nodules to a multinodular variety that exhibits local infiltration. Recent advances in molecular oncology have defined a gene, nm23, expressed in normal cells which is responsible for inhibiting infiltration. The aim of this study was to investigate the expression of nm23 in a series of 52 giant cell tumours using immunohistochemistry and to assess its prognostic potential, nm23 expression was absent in 21% of tumours and this was associated with a highly significant risk of local recurrence ( P<0.0001). Multivariate analysis of outcome showed nm23 expression to be more reliable than other clinicopathological parameters for predicting outcome. This immunohistochemieal test for nm23 is easily performed on standard paraffin sections and is recommended as an accurate prognostic marker for giant cell tumours of tendon sheath.

Outcomes of surgery for giant cell tumors of the tendon sheath within the hand.

2020 ◽  
Vol 92 (5) ◽  
pp. 1-5
Author(s):  
Andrzej Żyluk ◽  
Ada Owczarska
Keyword(s):  
Giant Cell ◽  
Recurrence Rate ◽  
Surgical Margin ◽  
Tendon Sheath ◽  
High Rate ◽  
High Recurrence Rate ◽  
Giant Cell Tumors ◽  
Proliferative Lesion

Giant cell tumor of the tendon sheath is the most common benign proliferative lesion involving the upper limb, characterised by relatively high recurrence rate after surgery. The objective of the study was a retrospective analysis of outcomes of the operative treatment of these tumours, in a long-term (a mean of 4,2 year) follow-up. Patients and methods. Preoperative examination was performed in 58 patients, 36 females (62%) and 22 males (38%), in a mean age of 41 years, and treatment outcomes were assessed in 47 persons (81% of the operated on), at a mean of 4,2 year follow-up. The final assessment was performed in a form of phone interview. Results. The tumours most frequently were located in fingers - 42 cases (72%). In 31 patients (53%) the lesion had well-defined capsule, and in 11 (19%) a satellite nodules were found around the main tumour. A total of 9 relapses (21%) occurred, all within first 2 years following surgery. Two patients had a next episode of recurrence after the second operation. In 8 out of the 9 patients with the recurrence, the primary lesion had not well-defined capsule. In 38 patients who had no relapse, 31 were completely symptom-free, whereas 7 complained from mild pain of the scar and/or numbness of the part of the involved finger. Conclusions. The main factor influencing the high rate of recurrence was incomplete tumour excision, what resulted from inadequately accurate surgery and the tumour morphology (having no well-defend capsule). The role of operating with the use of magnifying devices and keeping greater surgical margin at resection of the non-capsulated lesions was emphasised, what may translate into reducing of the recurrence rate.

Sign in / Sign up

Export Citation Format

Share Document